Immediate access to French wellness market and established portfolio
of hemp-based wellness products
LONDON–(BUSINESS WIRE)–EMMAC Life Sciences Ltd, the European independent medical cannabis
company, is pleased to announce the acquisition of GreenLeaf, a French
hemp-based wellness company. The acquisition provides EMMAC with an
established e-commerce and retail distribution model in France as well
as a proven portfolio of hemp-based wellness products, under the Hello
Joya brand.
The GreenLeaf team will strengthen EMMAC’s regional presence in France,
led by General Manager Francois-Xavier Nottin. Aurélien Delecroix,
founder of GreenLeaf, is also the founder and President of Le Syndicat
du Chanvre /The Hemp Trade Union, created in 2018 to bring together the
professional actors of the hemp and therapeutic hemp sectors in France
(production, processing, distribution) and defend their interests in the
construction of these emerging markets.
Antonio Costanzo, CEO of EMMAC, commented: “We are pleased to
announce the acquisition of GreenLeaf and welcome Aurélien and the team
to EMMAC. France is an important market for EMMAC and we are confident
that GreenLeaf’s established distribution model, experienced team and
premium product portfolio will advance our plans for strategic growth in
the region. We look forward to incorporating the Hello Joya products
into our Wellness range, as EMMAC capitalises on the rapid growth across
Europe as the cosmetic, food and nutraceutical industries incorporate
the active principles of the cannabis plant to its products.”
Aurélien Delecroix, founder of GreenLeaf, said: “We are delighted
to have joined EMMAC today. We believe our vision to help consumers
discover benefits of hemp, by producing, shaping and marketing high
quality hemp-based products aligns with EMMAC’s vision of bringing
premium quality wellness and CBD products to market, and we look forward
to extending our range for customers in France and across Europe.”
GreenLeaf is EMMAC’s second wellness company acquisition, following on
from the acquisition of Blossom, the premium wellness CBD company in
Switzerland acquired earlier in 2019.
-Ends-
About EMMAC
EMMAC is the European medical cannabis company, working to join together
the latest science and research with cutting-edge cultivation,
extraction and production. With supply and distribution partnerships
throughout Europe, EMMAC is working to establish itself as both a
thought leader in the industry, as well as the European leader in the
production and supply of medical cannabis, hemp and other derivative
products.
CAUTIONARY STATEMENT
All statements, other than statements of historical fact, in this news
release are forward-looking statements that involve various risks and
uncertainties, including, without limitation, statements regarding
potential values, the future plans and objectives of EMMAC Life Sciences
Ltd. There can be no assurance that such statements will prove to be
accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those
anticipated in such statements. These and all subsequent written and
oral forward-looking statements are based on the estimates and opinions
of management on the dates they are made and are expressly qualified in
their entirety by this notice. EMMAC Life Sciences Ltd assumes no
obligation to update forward-looking statements should circumstances or
management’s estimates or opinions change.
Contacts
For scientific enquiries please contact [email protected]
For
general enquiries please contact [email protected]
or visit www.emmac.com
Media enquiries
Buchanan
Henry Harrison-Topham /
Jamie Hooper / Ariadna Peretz
[email protected]
Tel:
+44 (0) 20 7466 5000
www.buchanan.uk.com
